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Abstract
Background: Serum uric acid concentrations are higher in patients with established coronary
artery disease than in healthy controls. This study aimed to determine the role of uric acid in
predetermining coronary artery disease in young patients with acute myocardial infarction (AMI).
Methods: This study included 80 of 1612 patients who applied our hospital between January
2000 and December 2005. All of the patients were under 35 years old, diagnosed with AMI
by clinical and laboratory findings, and had coronary angiography. The study population was
divided into two groups, the first having critical coronary artery disease (group I) and the
second having normal coronary arteries (group II). Then we compared these groups with age,
body mass index, risk factors, serum protein C, protein S, antithrombin III, creatinine and
uric acid levels.
Results: Myocardial infarction was located in 65% anterior, 15% inferior, 15% inferiolateral
and 5% high lateral, respectively. Forty five % of patients had critical coronary artery disease
(group I, n = 36) and 55% had normal coronary arteries (group II, n = 44). There were no
differences in the two groups with regard to body mass index, family history, hypertension,
smoking, cholesterol level, triglyceride level and creatinine level, lack of protein C, lack of protein S
or lack of antithrombin III. Serum uric acid levels were found to be higher in group I (7.0 ±
± 1.4 mg/dL) than in group II (4.9 ± 1.1 mg/dL; p = 0.003).
Conclusions: This study showed that high serum uric acid levels were associated with critical
coronary artery disease in young patients (< 35 years) with AMI (Cardiol J 2008; 15: 21–25)
Key words: acute myocardial infarction, young patients, uric acid, coronary
artery disease
Introduction
Acute myocardial infarction (AMI) is an irre-
versible myocardial injury and necrosis caused by
serious and long-term ischemia. AMI is generally
seen in middle-aged people with high risk factors
for coronary artery disease. It is difficult to deter-
mine the real rate in the younger age population but
it is known that it is less common and only 5% of
AMI patients are less than 40 years old [1].
Coronary anatomy is normal in 30% of young
AMI patients [2]. The presence of normal coronary
anatomy is related to coronary vasospasm, embo-
lism from endocardium or heart vessels, platelet
aggregation or spontaneous lysis of thrombus [3].
Due to the high rate of normal coronary angiography
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in young patients, it is necessary to evaluate some
parameters for the early prediction of coronary ar-
tery disease. Therefore, we aimed to evaluate the
relationship between coronary anatomy and risk
factors, clinical properties, serum uric acid (UA),
protein C, protein S and antithrombin III (AT III) lev-
els to determine coronary artery disease predictors
in AMI patients less than 35 years of age.
Methods
Patient population
This study included 80 of 1612 patients who
applied our hospital between January 2000 and De-
cember 2005. These 80 patients were less than
35 years old, diagnosed as AMI with clinical and lab-
oratory findings, and had coronary angiography.
Oral informed consent was obtained from all sub-
jects. All patients were admitted within 12 h after
the onset of AMI. Diagnosis of AMI was established
by ST segment elevation, defined subsequently in
more than two leads, associated with typical chest
pain and confirmed by an elevation of serum creat-
ine kinase MB isoenzyme greater than two times
the normal upper limit during the patient’s clinical
course. Thrombolytic treatment was applied to all
patients. Cardiac catheterization was performed
after the patient’s clinical status was stabilized on
the fifth or sixth day of hospitalization. Coronary
angiograms were evaluated by two experienced
angiographers (E.T., M.A.) blinded to the charac-
teristics of the patients.
The study protocol was approved by the local
ethical committee and informed consent was ob-
tained from each patient.
Cardiac catheterization
Coronary angiography is performed with a Phil-
lips Multidiagnosis C2 (Philips, Eindhoven, Nether-
lands) device by using ‘Sones’ or ‘Jutkins’ tech-
niques. Obstruction greater than 50% in coronary
vessels was accepted as critical coronary artery
disease. Left ventriculography was performed us-
ing standard techniques. The study patients were
divided into two groups, the first having critical
coronary artery disease (group I) and the second
having normal coronary arteries (group II), accord-
ing to their coronary angiographies.
Analysis of hematological profile
Blood samples were taken as soon as patients
were admitted to hospital, and the samples were
immediately analyzed. Quantitative measurements
of protein C and AT III were performed by colori-
metric assay using coamatic protein C from Chro-
mogenix (Mölndal, Sweden), Stachrom AT III au-
tomated, and Stachrom PLG (Diagnostica Stoga,
Asnieres, France), respectively. Quantitative deter-
mination of functional protein S, based on the inhibi-
tion of factor Va, was established using a clotting as-
say of protein S (Staclot protein S, Diagnostica Stage).
Analysis of serum uric acid levels
and other laboratory data
Serum UA levels of patients were measured
with a Technicon SMA 12/60 autoanalyser (Tech-
nicon Instruments, Tarrytown, New York, USA)
device by spectrophotometric method.
Standard clinical chemistry techniques were
used to measure creatinine, total cholesterol, high-
-density lipoprotein (HDL), low-density lipoprotein
(LDL) and triglyceride levels. We evaluated the
presence of hypertension (systolic blood pressure;
140 mm Hg and/or diastolic blood pressure; 95 mm Hg
and/or receiving antihypertensive agents).
Groups were compared in terms of hyperten-
sion, cholesterol level, triglyceride level, creatinine
level, smoking, family history, age, body mass index,
serum UA, protein C, protein S and AT III levels.
Statistical analysis
Quantitative values are expressed as mean ±
± SD and were compared using Mann Whitney U
test. The c2 test, Fisher’s exact test and logistic re-
gression analysis were used for analysis of categor-
ical data. For all tests, p > 0.05 was designated non-
significant, and a value of p < 0.05 was considered
statistically significant. The SPSS statistical soft-
ware package (version 10.0) was used to perform
all statistical calculations.
Results
All of the patients were male with an average
age of 30.2 ± 4.8 years. Smoking, family history,
hypertension were in 95%, 20%, 15% of patients,
respectively. None of the patients had diabetes
mellitus. AMI was localized in 65% anterior, 15%
inferior, 15% inferolateral and 5% high lateral. Ac-
cording to the coronary angiography, 55% had nor-
mal coronary arteries (group II, n = 44) and 45% had
critical coronary artery disease (group I, n = 36).
In group I, 20 patients had one, 12 had two and
4 had three vessel diseases. There were no differ-
ences in the two groups regarding body mass in-
dex, family history, hypertension, smoking, total
cholesterol, HDL and LDL levels, triglyceride level,
creatinine level, lack of protein C, lack of protein S
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and lack of AT III (p > 0.05). Serum UA levels were
found to be higher in group I (7.0 ± 1.4 mg/dL) than
in group II (4.9 ± 1.1 mg/dL; p = 0.003). The groups
were compared regarding ehematological parameters
and clinical properties as shown in Tables 1 and 2.
Discussion
This study showed that high serum UA levels
were related to critical coronary artery disease in
young patients with AMI. Roskamm et al. [3]
showed that the presence of normal coronary ana-
tomy in young AMI patients is 17–30%. Normal cor-
onary arteries, after AMI, are related to coronary
vasospasm, embolus arising from endocardium or
heart vessels, platelet aggregation or spontaneous
lysis of thrombus [2]. Smoking is the most common
risk factor in AMI patients with normal coronary
anatomy. It impairs endothelium derived vasodila-
tion mechanisms and vasospasm in coronary arter-
ies [4, 5]. Vasospasm is supposed to be the most
important physiopathological mechanism in these
patients [6, 7]. Hypercoagulopathy and fibrinolytic
system defects are also in the etiology. A lack of
protein S is responsible these effects [8]. Protein S
is an endothelial derived protein C co-factor, and
these two proteins are coagulation inhibitors. Lack
of AT III and high levels of plasminogen activator
inhibitor-1 may sometimes also be a reason [9].
In a study comparing young AMI patients and normal
healthy patients, there were no significant differ-
ences in protein C, protein S and AT III levels be-
tween coronary a artery lesion group, normal coro-
nary artery group and a normal healthy group [10].
We studied these ehematological risk factors in our
study, but we could not find any significant differ-
ence in protein C, S and AT III levels between two
groups either.
In men, serum UA concentrations rise during
puberty from childhood mean values of 3.5 mg/dL
to adult levels of 4.0 ± 2.0 mg/dL. Hyperuricemia
is defined as a serum UA level greater than 7.0 mg/dL,
as measured by the automated enzymatic (uricase)
method [11, 12].
Over recent years there has been renewed
debate concerning the nature of the association
between raised serum UA concentrations and car-
diovascular disease (CVD). Several large studies
have identified the value of serum UA concentra-
tions in young populations in predicting the risk of
CVD, such as AMI [13, 14]. Torun et al. [15] showed
that serum UA concentrations were higher in pa-
tients with established coronary artery disease
compared with healthy controls. We were also
shown that serum UA levels are higher in young
patients (< 35 years) with established critical cor-
onary artery disease. Multivariate analysis of data
from the MONICA cohort of 1044 males showed
a significant association between raised serum UA
and cardiovascular mortality, independent of body
mass index, serum cholesterol concentration, hyper-
tension, diuretic use, alcohol intake and smoking
Table 1. Parameters of study groups (mean ± SD).
Clinical characteristics Group I (n = 36) Group II (n = 44) p
Age (years) 32.7 ± 1.7 28.1 ± 5.6 0.120
Body mass index [kg/m2] 28.01 ± 4.1 28.34 ± 4.0 0.650
Family history 8 (22%) 8 (18%) 0.320
Smoking 36 (100%) 40 (90%) 0.200
Hypertension 8 (22%) 4 (9%) 0.300
Total cholesterol [mg/dL] 196 ± 48 180 ± 32 0.780
LDL cholesterol [mg/dL] 133 ± 42 142 ± 43 0.220
HDL cholesterol [mg/dL] 39 ± 12 38 ± 18 0.235
Triglycerides [mg/dL] 117 ± 62 108 ± 59 0.440
Creatinine [mg/dL] 1.0 ± 0.2 1.0 ± 0.1 0.700
HDL — high-density lipoprotein, LDL — low-density lipoprotein
Table 2. Hematological parameters and uric acid
levels of study groups (mean ± SD).
Variables Group I Group II p
(n = 36)  (n = 44)
Uric acid [mg/dL] 7.0 ± 1.4 4.9 ± 1.1 0.003
Lack of protein C 8 (22%) 4 (9%) 0.300
Lack of protein S 4 (11%) 4 (9%) 0.600
Lack of antithrombin III 2 (6%) 4 (9%) 0.220
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habit [16]. A retrospective analysis of the NHANES
data [17] followed 5 926 patients for an average of
16.4 years and found that increased serum UA lev-
els were independently and significantly associat-
ed with cardiovascular mortality in both men and
women. These findings suggest a relationship be-
tween high serum UA levels and coronary artery
disease, although the underlying mechanisms re-
main unclear.
Nitric oxide, which is known to be a potent
vasodilatator, is important for maintaining vascular
tone. Synthesis of nitric oxide is disrupted and its
degradation is accelerated by excessive free radi-
cal activity. This condition disrupts functions of
endothelium dependent vasodilatation; a condition
known as endothelial dysfunction. Endothelial dys-
function is the first step for the beginning of athero-
sclerosis [18]. Thus, increased oxidative stress ap-
pears to play an important role in the development
and progression of atherosclerosis [19]. Serum UA
has antioxidant properties and contributes to free
radical scavenging activity in human serum. When
uric acid interacts with peroxynitrite to form a sta-
ble nitric oxide donor, vasodilatation increases and
the potential for peroxynitrite-induced oxidative
damage decreases [20]. Thus, UA can be protective
against oxidative stresses, but it can also lead di-
rectly or indirectly to vascular injury.
Ishizaka et al. [21] showed that the association
between serum UA and high brachial-ankle pulse
wave velocity was at least in part independent of con-
ventional risk factors for atherosclerosis. What is the
possible underlying mechanism that links hyperuri-
cemia and arterial stiffening? It has been reported that
UA promotes vascular smooth muscle proliferation and
upregulates the expression of platelet-derived growth
factor and monocyte chemoattractant protein-1 [22].
Hypoxanthine is converted to uric acid via xanthine.
This reaction can be catalyzed by xanthine hydroge-
nase and xanthine oxidase, the latter of which produc-
es uric acid and superoxide.
Thus, it is possible that, in certain diseased
conditions, hyperuricemia is accompanied by the
increased production of reactive oxygen species,
which may result in the modulation of vascular con-
tractility [23]. Consistent with this is the notion that
allopurinol, a xanthine oxidase inhibitor, not only
reduces the serum UA levels but also improves
vascular endothelial function in patients with chron-
ic heart failure [24]. Another possible explanation
is that hyperuricemia may induce endothelial dys-
function by decreasing the production of nitric
oxide in the vascular endothelial cells [25].
Adenosine synthesized locally by vascular
smooth muscle in cardiac tissue is rapidly degrad-
ed by the endothelium to UA, which undergoes rap-
id efflux to the vascular lumen due to low intracel-
lular PH and negative membrane potential [26]. Uric
acid synthesis is increased in vivo under ischemic
conditions, and therefore elevated serum UA may
act as a marker of underlying tissue ischemia.
In human coronary circulation, hypoxia, caused by tran-
sient coronary artery occlusion, leads to an increase
in the local circulating concentration of UA [27].
In conclusion, elevated serum UA may be a marker
of local and systemic tissue ischemia and provides
one possible explanation for a non-causal associa-
tive link between hyperuricemia and cardiovascu-
lar disease.
Conclusions
In conclusion, high serum UA levels are asso-
ciated with critical coronary artery disease in young
patients (< 35 years) with AMI. Nevertheless, this
finding should be supported by  research that is
more extensive in order to put it into practice.
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